World Health Organization. Cardiovascular diseases (CVDs). Fact 6 sheet. http://www.who.int/mediacentre/factsheets/fs317/en (accessed 22/5/17).
2.
FerenceBAHNGinsbergGrahamILow-density lipoproteins 7 cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel.Eur 8 Heart J2017. Epub ahead of print 24 April
3.
Cholesterol Treatment Trialists' CollaboratorsThe effects of lowering LDL cholesterol with statin therapy in people at low risk of 9 vascular disease: meta-analysis of individual data from 27 randomised trials.Lancet2012; 380: 581-90.
4.
Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA2009; 302: 1993-2000.
5.
Cholesterol Treatment Trialists' Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet2005; 366: 1267-78.
6.
FerenceBAJGRobinsonBrookRDVariation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.N Engl J Med 2016; 375: 2144-53.
7.
CannonCPBlazingMAGiuglianoRPEzetimibe Added to Statin Therapy after Acute Coronary Syndromes.N Engl J Med2015; 372: 2387-97.
8.
SabatineMSGiugliano RP KeechACEvolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med2017; 376: 1713-22.
9.
Cholesterol Treatment Trialists' CollaborationEfficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170 000 participants in 26 randomised trials.Lancet2010; 376: 1670-81.
